Brian Low Financial Group LLC Makes New $1.50 Million Investment in Eli Lilly and Company $LLY

Key Points

• Brian Low Financial Group LLC has made a new investment in Eli Lilly and Company, purchasing 1,928 shares valued at approximately $1.5 million, making it the firm's 15th largest holding.
• Insiders have been actively acquiring shares, with Director J Erik Fyrwald buying 1,565 shares and Jamere Jackson acquiring 200 shares, increasing their holdings in the company.
• Analysts have recently adjusted their price targets for Eli Lilly, with a consensus target price of $938.61 and ratings from "Strong Buy" to "Hold" among various firms.

Brian Low Financial Group LLC purchased a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the second quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor purchased 1,928 shares of the company's stock, valued at approximately $1,503,000. Eli Lilly and Company makes up 1.4% of Brian Low Financial Group LLC's investment portfolio, making the stock its 15th biggest holding.

Several other hedge funds have also recently made changes to their positions in LLY. Hobbs Wealth Management LLC lifted its holdings in shares of Eli Lilly and Company by 0.8% in the 1st quarter. Hobbs Wealth Management LLC now owns 1,459 shares of the company's stock valued at $1,205,000 after buying an additional 12 shares during the period. Hixon Zuercher LLC grew its holdings in Eli Lilly and Company by 0.7% during the first quarter. Hixon Zuercher LLC now owns 1,789 shares of the company's stock worth $1,477,000 after acquiring an additional 12 shares during the period. O Brien Wealth Partners LLC raised its position in Eli Lilly and Company by 25.5% in the first quarter. O Brien Wealth Partners LLC now owns 59 shares of the company's stock worth $49,000 after acquiring an additional 12 shares in the last quarter. Ascent Capital Management LLC grew its stake in shares of Eli Lilly and Company by 2.5% during the 1st quarter. Ascent Capital Management LLC now owns 495 shares of the company's stock worth $409,000 after purchasing an additional 12 shares during the period. Finally, Willner & Heller LLC lifted its stake in shares of Eli Lilly and Company by 1.5% in the first quarter. Willner & Heller LLC now owns 854 shares of the company's stock valued at $705,000 after purchasing an additional 13 shares during the period. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, Director J Erik Fyrwald bought 1,565 shares of the stock in a transaction on Tuesday, August 12th. The stock was purchased at an average cost of $642.33 per share, with a total value of $1,005,246.45. Following the purchase, the director owned 74,578 shares of the company's stock, valued at approximately $47,903,686.74. The trade was a 2.14% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. Also, Director Jamere Jackson purchased 200 shares of Eli Lilly and Company stock in a transaction on Friday, August 8th. The shares were acquired at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the purchase, the director owned 9,402 shares in the company, valued at approximately $6,013,143.12. This trade represents a 2.17% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have acquired 4,514 shares of company stock valued at $2,894,841 in the last 90 days. Insiders own 0.13% of the company's stock.

Analysts Set New Price Targets

LLY has been the topic of several recent analyst reports. Weiss Ratings restated a "hold (c+)" rating on shares of Eli Lilly and Company in a research report on Friday. Daiwa America downgraded Eli Lilly and Company from a "strong-buy" rating to a "hold" rating in a research note on Sunday, August 17th. Deutsche Bank Aktiengesellschaft decreased their target price on Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating on the stock in a research report on Monday, August 11th. HSBC upped their target price on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. Finally, BMO Capital Markets lifted their price target on Eli Lilly and Company from $840.00 to $930.00 and gave the stock an "outperform" rating in a research note on Monday, October 20th. One analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and nine have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of "Moderate Buy" and a consensus target price of $938.61.

Eli Lilly and Company Stock Up 0.6%

LLY opened at $825.86 on Friday. The firm has a market cap of $781.65 billion, a P/E ratio of 53.98, a PEG ratio of 1.18 and a beta of 0.47. The business's fifty day simple moving average is $768.01 and its 200 day simple moving average is $768.14. Eli Lilly and Company has a 52 week low of $623.78 and a 52 week high of $935.63. The company has a quick ratio of 1.00, a current ratio of 1.28 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $6.31 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The company had revenue of $15.56 billion for the quarter, compared to analyst estimates of $14.40 billion. During the same period in the prior year, the firm earned $3.92 EPS. The firm's quarterly revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. As a group, equities research analysts anticipate that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.